search
Back to results

Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

Primary Purpose

Poliomyelitis

Status
Completed
Phase
Phase 2
Locations
Philippines
Study Type
Interventional
Intervention
Inactivated Poliomyelitis vaccine (IMOVAX)
Inactivated Poliomyelitis vaccine (IMOVAX)
Sponsored by
Sanofi Pasteur, a Sanofi Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Poliomyelitis focused on measuring Poliomyelitis, intradermal

Eligibility Criteria

42 Days - 50 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Inclusion Criteria to be checked at the screening visit (SC):
  • Aged 0 to 7 days on the day of screening
  • Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg
  • Informed consent form signed by the parent(s) or other legally acceptable representative
  • Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures
  • Inclusion Criteria to be checked at the randomization visit (V01):
  • Aged 42 to 50 days on the day of inclusion
  • Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures

Exclusion Criteria:

  • Exclusion Criteria to be checked at the screening visit (SC):
  • Planned participation in another clinical trial during the present trial period
  • Illness that could interfere with trial conduct or completion, in the opinion of the investigator
  • Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response
  • History of seizures
  • Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity
  • Thrombocytopenia or bleeding disorder contraindicating IM injection
  • Exclusion Criteria to be checked at the randomization visit (V01):
  • Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
  • Planned participation in another clinical trial during the present trial period
  • Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
  • Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
  • Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator
  • Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response
  • Receipt or planned receipt of any vaccine in the 4 weeks preceding or following any trial vaccination (except BCG, DTP-Hib or Hepatitis B vaccines, which can not be given within 10 days before or after any study vaccination)
  • History of seizures
  • Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity
  • History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)
  • Previous vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine
  • Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) injection
  • Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A

Group B

Arm Description

Outcomes

Primary Outcome Measures

The non-inferiority of fractional doses of IMOVAX Polio administered intradermally versus full doses of IMOVAX Polio administered intramuscularly, in terms of seroprotection rates (polio types 1 2 and 3) one month after the three-dose primary vaccination

Secondary Outcome Measures

Immunogenicity: To assess and describe in each group the immunogenicity of the study vaccines one month after the three-dose primary vaccination Safety: To describe in each group the safety after each dose of the study vaccines

Full Information

First Posted
January 17, 2008
Last Updated
January 20, 2014
Sponsor
Sanofi Pasteur, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT00604058
Brief Title
Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly
Official Title
Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine Administered Intradermally vs Full Doses of Inactivated Poliomyelitis Vaccine Administered Intramuscularly in Healthy Philippines Infants
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The present study intends to investigate the use of fractional doses of sanofi pasteur's IMOVAX Polio injected intradermally. The primary objective will be to demonstrate the non-inferiority of fractional doses of IMOVAX Polio administered intradermally versus full doses of IMOVAX Polio administered intramuscularly, in terms of seroprotection rates (polio types 1, 2 and 3) one month after the three-dose primary vaccination administered at 6-10-14 weeks of age.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Poliomyelitis
Keywords
Poliomyelitis, intradermal

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
236 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Experimental
Arm Title
Group B
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
Inactivated Poliomyelitis vaccine (IMOVAX)
Other Intervention Name(s)
IMOVAX Polio (IPV) vaccine
Intervention Description
Fractional dose (1/5th) 0.1 mL, intradermally
Intervention Type
Biological
Intervention Name(s)
Inactivated Poliomyelitis vaccine (IMOVAX)
Other Intervention Name(s)
IMOVAX Polio (IPV) vaccine
Intervention Description
A full dose, 0.5 mL, intramuscular
Primary Outcome Measure Information:
Title
The non-inferiority of fractional doses of IMOVAX Polio administered intradermally versus full doses of IMOVAX Polio administered intramuscularly, in terms of seroprotection rates (polio types 1 2 and 3) one month after the three-dose primary vaccination
Time Frame
1 Month Post-vaccination
Secondary Outcome Measure Information:
Title
Immunogenicity: To assess and describe in each group the immunogenicity of the study vaccines one month after the three-dose primary vaccination Safety: To describe in each group the safety after each dose of the study vaccines
Time Frame
1 Month post-vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
42 Days
Maximum Age & Unit of Time
50 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria to be checked at the screening visit (SC): Aged 0 to 7 days on the day of screening Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg Informed consent form signed by the parent(s) or other legally acceptable representative Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures Inclusion Criteria to be checked at the randomization visit (V01): Aged 42 to 50 days on the day of inclusion Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures Exclusion Criteria: Exclusion Criteria to be checked at the screening visit (SC): Planned participation in another clinical trial during the present trial period Illness that could interfere with trial conduct or completion, in the opinion of the investigator Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response History of seizures Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity Thrombocytopenia or bleeding disorder contraindicating IM injection Exclusion Criteria to be checked at the randomization visit (V01): Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response Receipt or planned receipt of any vaccine in the 4 weeks preceding or following any trial vaccination (except BCG, DTP-Hib or Hepatitis B vaccines, which can not be given within 10 days before or after any study vaccination) History of seizures Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically) Previous vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) injection Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Sanofi Pasteur Inc
Official's Role
Study Director
Facility Information:
City
Quezon city
State/Province
Manila
Country
Philippines

12. IPD Sharing Statement

Citations:
PubMed Identifier
22153001
Citation
Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012 Feb;16(2):e110-6. doi: 10.1016/j.ijid.2011.10.002. Epub 2011 Dec 5.
Results Reference
derived
Links:
URL
http://www.sanofipasteur.com
Description
Related Info

Learn more about this trial

Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

We'll reach out to this number within 24 hrs